These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 87265)

  • 41. Murine Pam 212 cutaneous squamous cell carcinoma is nonimmunogenic in normal syngeneic hosts and resistant to immune effector mechanisms.
    Chen Z; Rosten SI; Lord EM; Gaspari AA
    Reg Immunol; 1993; 5(5):285-92. PubMed ID: 8148238
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immune selection in murine tumors. Ph.d thesis.
    Svane IM; Engel AM
    APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Rat prostate carcinoma 11095-A: profile of organ- and tumor-specific antigens.
    Lande IJ; Feldbush TL; Lubaroff DM; Bonney WW
    Natl Cancer Inst Monogr; 1978 Dec; (49):283-7. PubMed ID: 86165
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of immunosuppression on the rejection of methylcholanthrene tumor isografts.
    Jacobs SC; McLaughlin AP; Gittes RF
    J Surg Oncol; 1977; 9(4):353-7. PubMed ID: 895157
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cross-immunity among allogeneic tumors in rats immunized with gamma-irradiated ascites tumors.
    Sato T; Suga M; Kudo H; Waga T; Ogasawara M; Usubuchi I
    Tohoku J Exp Med; 1980 Aug; 131(4):387-91. PubMed ID: 7466805
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Spontaneous tumor rejection is not always due to a complete cellular rejection.
    Dullens HF; Schakenrad S; Den Otter W
    Exp Pathol; 1987; 31(1):33-8. PubMed ID: 3569480
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Teratocarcinoma cell variants rejected by syngeneic mice: protection of mice immunized with these variants against other variants and against the original malignant cell line.
    Boon T; Van Pel A
    Proc Natl Acad Sci U S A; 1978 Mar; 75(3):1519-23. PubMed ID: 274738
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antitumor immunity. II. Viability, tumorigenicity, and immunogenicity of neuraminidase-treated tumor cells: effective immunization of animals with a tumor vaccine.
    Ray PK; Thakur VS; Sundaram K
    J Natl Cancer Inst; 1976 Jan; 56(1):83-7. PubMed ID: 1255753
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immunosuppression and the development of malignancies of the upper airway and related structures.
    Harris JP; Penn I
    Laryngoscope; 1981 Apr; 91(4):520-8. PubMed ID: 7012492
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Co-existence of allogeneic tumour growth and homograft immunity in man.
    Southam CM
    Eur J Cancer (1965); 1968 Oct; 4(5):507-11. PubMed ID: 5760731
    [No Abstract]   [Full Text] [Related]  

  • 51. Non-immunogenicity of enucleated rat hepatoma cells in syngeneic animals.
    Gerlier D; Price M; Baldwin RW
    Br J Cancer; 1981 Nov; 44(5):725-32. PubMed ID: 6797456
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tumour-specific immunity against spontaneous rat tumours.
    Baldwin RW
    Int J Cancer; 1966 May; 1(3):257-64. PubMed ID: 5944065
    [No Abstract]   [Full Text] [Related]  

  • 53. Immunoprevention of large bowel cancer: an animal model.
    Sjögren HO
    Cancer; 1980 Mar; 45(5 Suppl):1229-33. PubMed ID: 7357514
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Epitope masking of rat esophageal carcinoma tumor-associated antigen by certain coexisting glycolipid and phospholipid molecules: a potential mechanism for tumor cell escape from the host immune responses.
    Jamasbi RJ; Wan X; Stoner GD
    Cancer Immunol Immunother; 1994 Feb; 38(2):99-106. PubMed ID: 7508339
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The effect of passage in vitro and in vivo on the properties of murine fibrosarcomas I. Tumorigenicity and immunogenicity.
    Woodruff MF; Hodson BA
    Br J Cancer; 1985 Feb; 51(2):161-9. PubMed ID: 3966976
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Implications of tumor progression on clinical oncology.
    Welch DR; Tomasovic SP
    Clin Exp Metastasis; 1985; 3(3):151-88. PubMed ID: 3902300
    [No Abstract]   [Full Text] [Related]  

  • 57. Dynamic heterogeneity: experimental metastasis studies with RIF-1 fibrosarcoma.
    Korycka BM; Hill RP
    Clin Exp Metastasis; 1989; 7(1):107-16. PubMed ID: 2908825
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Increase in immunogenicity with concomitant loss of tumorigenicity of respiratory tract carcinomas during in vitro culture.
    Jamasbi RJ; Nettesheim P
    Cancer Res; 1979 Jul; 39(7 Pt 1):2466-70. PubMed ID: 87265
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Demonstration of cross-reacting tumor rejection antigens in chemically induced respiratory tract carcinomas in rats.
    Jamasbi RJ; Nettesheim P
    Cancer Res; 1977 Nov; 37(11):4059-63. PubMed ID: 71203
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Demonstration of cellular and humoral immunity to transplantable carcinomas derived from the respiratory tract of rats.
    Jamasbi RJ; Nettesheim P; Kennel SJ
    Cancer Res; 1978 Feb; 38(2):261-7. PubMed ID: 340026
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.